PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2021/59 - Grupo Triton / Grupo Clinigen
Acquired
Clinigen Group Plc
Description
It is a pharmaceutical services and products company, which focuses its activity on providing access to its own medicines and third-party medicines in order to respond to unmet medical needs and/or for use in clinical trials.
Acquiring
Triley Bidco Limited
Description
It is a company indirectly controlled by Triton Fund V, Jersey, a private equity firm that manages a multiplicity of funds and independent investment companies.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C211 - Manufacture of basic pharmaceutical products
Applicable legislation
Art. 37(1)(c) (Law 19)
Notification thresholds
Turnover threshold
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description
The notified concentration consists of the acquisition of sole control over Clinigen Group by Triley Bidco.
Timeline
2022-01-18
The AdC issued a non-opposition decision to the merger 59/2021 - Group Triton / Group Clinigen
2021-12-30
The Triton Group notifies the acquisition of sole control over the Clinigen Group.
Click here to see your activities